98%
921
2 minutes
20
In the proteasome holoenzyme, the hexameric ATPases (Rpt1-Rpt6) enable degradation of ubiquitinated proteins by unfolding and translocating them into the proteolytic core particle. During early-stage proteasome assembly, individual Rpt proteins assemble into the hexameric "Rpt ring" through binding to their cognate chaperones: Nas2, Hsm3, Nas6, and Rpn14. Here, we show that Rpt ring assembly employs a specific ubiquitination-mediated control. An E3 ligase, Not4, selectively ubiquitinates Rpt5 during Rpt ring assembly. To access Rpt5, Not4 competes with Nas2 until the penultimate step and then with Hsm3 at the final step of Rpt ring completion. Using the known Rpt-chaperone cocrystal structures, we show that Not4-mediated ubiquitination sites in Rpt5 are obstructed by Nas2 and Hsm3. Thus, Not4 can distinguish a Rpt ring that matures without these chaperones, based on its accessibility to Rpt5. Rpt5 ubiquitination does not destabilize the ring but hinders incorporation of incoming subunits-Rpn1 ubiquitin receptor and Ubp6 deubiquitinase-thereby blocking progression of proteasome assembly and ubiquitin regeneration from proteasome substrates. Our findings reveal an assembly checkpoint where Not4 monitors chaperone actions during hexameric ATPase ring assembly, thereby ensuring the accuracy of proteasome holoenzyme maturation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310792 | PMC |
http://dx.doi.org/10.1073/pnas.1805353115 | DOI Listing |
Med Phys
August 2025
QuantIF AIMS, University of Rouen, Rouen, France.
Background: Patient-specific dosimetry in radiopharmaceutical therapy (RPT) offers a promising approach to optimize the balance between treatment efficacy and toxicity. The introduction of 360° CZT gamma cameras enables the development of personalized dosimetry studies using whole-body single photon emission computed tomography and computed tomography (SPECT/CT) data.
Purpose: This study proposes to validate the collapsed-cone superposition (CCS) approach against Monte Carlo (MC) simulations for whole-body dosimetry of [177Lu]Lu-PSMA-617 therapy in patients with metastatic castration resistant prostate cancer (mCRPC).
Cancer Imaging
July 2025
Department of Radiology and Nuclear Medicine; and Cancer Research Centre, Université Laval, Quebec City, QC, Canada.
Background: The tumour sink effect is a phenomenon whereby the sequestration of a radiopharmaceutical in cancer lesions leads to decreased activity concentration in the blood stream and organs. The aim of this sub-analysis of the prospective 3TMPO study (NCT04000776) was to investigate the tumour sink effect on prostate-specific membrane antigen (PSMA) PET imaging in a population of patients with metastatic castration-resistant prostate cancer (mCRPC).
Methods: Ninety-seven participants underwent Ga-PSMA-617 PET/CT imaging.
Eur J Nucl Med Mol Imaging
April 2025
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.
Introduction: Despite the potential of dosimetry in optimizing personalized radiopharmaceutical therapy (RPT), its limited clinical implementation impedes the development of simplified protocols for routine adoption. However, simplifications may introduce errors in dosimetry, prompting questions about their impact on clinical practice.
Materials And Methods: In this retrospective study, we analyzed data from 21 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who underwent multiple cycles of Lu-PSMA-617 RPT treatment.
Cancer Biother Radiopharm
April 2025
Department of Clinical Sciences Lund, Section for Oncology, Lund University, Lund, Sweden.
Prostate-specific membrane antigen (PSMA) is a target for diagnostic positron emission tomography (PET)-tracers and radiopharmaceutical therapy (RPT), for example, [Lu]Lu-PSMA-617, in prostate cancer. This autoradiography study investigates [Lu]Lu-PSMA-617 intratumoral distribution over time, compared with PSMA expression, proliferation (Ki67), and [Ga]Ga-PSMA-11, [F]F-PSMA-1007, [F]-fluorodeoxyglucose, and [F]-fluorocholine distribution. Mice with LNCaP, 22Rv1, or PC-3 PIP xenografts got [Lu]Lu-PSMA-617 i.
View Article and Find Full Text PDFJ Mol Biol
December 2024
Laboratory of Molecular Basis of Aging and Rejuvenation, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland. Electronic address:
The prefoldin complex is a heterohexameric, evolutionarily conserved co-chaperone that assists in folding of polypeptides downstream of the protein translation machinery. Loss of prefoldin function leads to impaired solubility of cellular proteins. The degradation of proteins by the proteasome is an integral part of protein homeostasis.
View Article and Find Full Text PDF